论文部分内容阅读
乙型肝炎病毒(HBV)在HBV相关性肝衰竭的发病过程中起重要作用,其发病机制主要为免疫活化机制,免疫抑制者体内则可见肝细胞的直接损伤。为此,抗病毒治疗的作用日益受到重视。近年来,有关抗病毒治疗的时机及药物选择成为研究热点,提倡应尽早、及时采用强效低耐药的核苷(酸)类似物(NUCs)治疗,同时注意长期治疗的药物安全性。优化治疗或初始联合治疗是目前两种主要策略。
Hepatitis B virus (HBV) plays an important role in the pathogenesis of HBV-related liver failure. The pathogenesis of Hepatitis B virus is mainly immune activation mechanism, while the immunosuppressors can directly damage the hepatocytes. To this end, the role of antiviral therapy is increasingly valued. In recent years, the timing of antiretroviral therapy and drug selection have become the research hotspots, advocating the treatment of nucleoside (acid) analogues (NUCs) with potent and low drug resistance as soon as possible and paying attention to the long-term drug safety. Optimized treatment or initial combination therapy is the current two main strategies.